HTA bodies

High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test

Huntington’s Disease Gets an Oral Target-Engagement Signal

A New CELMoD Raises the Bar in Relapsed Myeloma
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
